THEO-310 / Theolytics, The University of Sheffield - LARVOL DELTA

DEVELOPMENT OF A NOVEL ONCOLYTIC VIRUS -THEO-310 - SPECIALISED FOR TARGETING THE BONE MARROW TUMOUR MICROENVIRONMENT OF MULTIPLE MYELOMA PATIENTS (EHA 2023) - "Oncolytic virus therapies can offer this mechanistically distinct approach for myeloma patients, addressing the heterogeneity of the cancer and its microenvironment... Taken together, THEO-310 represents a new therapeutic option, with a highly differentiated mechanism independent of BCMA, for myeloma patients with relapsed refractory disease. Myeloma, Immunotherapy, Multiple myeloma"

Clinical • IO biomarker • Oncolytic virus • Tumor microenvironment • Hematological Malignancies • Infectious Disease • Measles • Multiple Myeloma • Oncology • IFNG • IL6

Theolytics Presents Data on THEO-260 for stromal rich carcinomas at ASCO and on THEO-310 for myeloma at EHA (PharmiWeb) - "In ovarian cancer murine models containing human CAFs and cancer cells, THEO-260 shows antitumor efficacy, with a complete reduction in tumour volume in subcutaneous and intraperitoneal systems, and superiority to standard of care. Virus activity is not restricted to ovarian cancer, with cell line data demonstrating killing in additional solid tumour types, including pancreatic, colorectal, lung, and breast cancer.....THEO-310 demonstrates efficacy in >80% of ex vivo bone marrow aspirates, across newly diagnosed, relapsed and refractory myeloma patients. In these experiments, TME immune modulation and superiority to ‘best-in-class’ oncolytic virus strains for myeloma, including the measles virus, was observed."

Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Evaluation of THEO-260 as a novel oncolytic virus therapy for treating stromal rich tumours. (ASCO 2023) - "Taken together, we present a preclinical data package for THEO-260 supporting progression to Phase I clinical trials."

Oncolytic virus • Stroma • Breast Cancer • Colorectal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Refractory Ovarian Cancer • Solid Tumor • CAFs • EGFR • IFNG • PD-L1